H. Mizuguchi

Human mass balance study of TAS-102 using 14C analyzed by accelerator mass spectrometry

E. Chu, S. Strychor, J. Beumer, 2016, Cancer Chemotherapy and Pharmacology.

Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Marc Peeters, Yasuhiro Shimada, Ben Tran, 2015, The New England journal of medicine.

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

C. Pericay, R. García-Carbonero, C. Grávalos, 2016, Clinical and Translational Oncology.

Brief Communication Prothrombin activation during carbon tetrachloride-induced acute liver injury in mice

T. Morita, Y. Yamazaki, J. Sonoda, 2002 .

Prothrombin activation during carbon tetrachloride-induced acute liver injury in mice.

T. Morita, Y. Yamazaki, J. Sonoda, 2002, Thrombosis research.

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

J. Bendell, J. Infante, R. Mayer, 2015, Cancer Chemotherapy and Pharmacology.

A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer

J. Ajani, M. Alsina, J. Feliu, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

TAS-102 versus placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial.

H. Lenz, J. Tabernero, B. Tran, 2015 .